Our data showed that the Lumipulse G pTau217 plasma assay could be used for distinguishing individuals at Intermediate (A+TMOD+) or Advanced (A+THIGH+) stages of AD vs those at lower stage or no AD with an AUC of 0.97, potentially aiding in their inclusion in or exclusion from a therapeutic trial or intervention. Here, TMOD1 is linked to Alzheimer disease.